Purine Nucleoside Phosphorylase Inhibition as a Novel Therapeutic Approach for B-Cell Lymphoid Malignancies

Seminars in Oncology

Volumn 34, Issue SUPPL. 5, 2007, Pages

  Furman, Richard R ^a   Hoelzer, Dieter ^b  

^a WEILL CORNELL MEDICAL CENTER   (United States)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CLADRIBINE; CLOFARABINE; CYTARABINE; DEXAMETHASONE; FLUDARABINE; FORODESINE; GUANOSINE TRIPHOSPHATE; IMMUNOSUPPRESSIVE ACID PROTEIN; NELARABINE; NUCLEOSIDE ANALOG; PENTOSTATIN; PREDNISONE; PURINE NUCLEOSIDE PHOSPHORYLASE INHIBITOR; RAPAMYCIN; TACROLIMUS; UNCLASSIFIED DRUG; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTHRALGIA; ARTICLE; ASTHENIA; B CELL LYMPHOMA; CANCER CHEMOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; COMBINATION CHEMOTHERAPY; CONSTIPATION; COUGHING; DIARRHEA; DRUG DOSE ESCALATION; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG STRUCTURE; ENZYME INHIBITION; FATIGUE; FEBRILE NEUTROPENIA; FEVER; GRAFT VERSUS HOST REACTION; HEADACHE; HUMAN; INSOMNIA; LEUKEMIA CELL; MONOTHERAPY; NAUSEA; OPTIMAL DRUG DOSE; PERIPHERAL EDEMA; PRIORITY JOURNAL; PRURITUS; SKIN LYMPHOMA; T CELL LYMPHOMA;

CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; DEOXYGUANINE NUCLEOTIDES; HUMANS; LEUKEMIA, B-CELL; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; PURINE NUCLEOSIDES; PURINE-NUCLEOSIDE PHOSPHORYLASE; PYRIMIDINONES;

EID: 37049039471     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2007.11.004     Document Type: Article

References (8)

1. Markert M.L. Purine nucleoside phosphorylase deficiency. Immunodef Rev 3 (1991) 45-81
2. Montgomery J.A. Inhibitors of purine nucleoside phosphorylase. Exp Opin Invest Drugs 3 (1994) 1303-1313
3. Bantia S., Miller P.J., Parker C.D., et al. Purine nucleoside phosphorylase inhibitor BCX-1777 (Immucillin-H)-A novel potent and orally active immunosuppressive agent. Int Immunopharmacol 1 (2001) 1199-1210
4. Bantia S., and Kilpatrick J.M. Purine nucleoside phosphorylase inhibitors in T-cell malignancies. Curr Opin Drug Discov Devel 7 (2004) 243-247
5. Kawasaki H., Carrera C.J., Piro L.D., et al. Relationship of deoxycytidine kinase and cytoplasmic 5′-nucleotidase to the chemotherapeutic efficacy of 2-chlorodeoxyadenosine. Blood 81 (1993) 597-601
6. Balakrishnan K., Nimmanapalli R., Ravandi F., et al. Forodesine, an inhibitor of purine nucleoside phosphorylase, induces apoptosis in chronic lymphocytic leukemia cells. Blood 108 (2006) 2392-2398
7. Furman R.R., Gandhi V.V., Bennett J.C., et al. Intravenous forodesine (BCX-1777), a novel purine nucleoside phosphorylase (PNP) inhibitor, demonstrates clinical activity in phase I/II studies in patients with B-cell acute lymphoblastic leukemia. Blood 104 suppl 1 (2004) 750a (abstr 2743)
8. Ritchie E., Gore L., Roboz G., et al. Phase II study of forodesine, a PNP inhibitor, in patients with relapsed or refractory B-lineage acute lymphoblastic leukemia (2006) Poster presented at the American Society of Hematology 48th Annual Meeting, Orlando, FL, December